GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021
May 06 2021 - 11:30AM
via NewMediaWire --
GeoVax Labs,
Inc. (NasdaqCM: GOVX), a biotechnology company
developing human immunotherapies and vaccines against infectious
diseases and cancers, announced today that management will
participate at the Benzinga Global Small Cap Conference being held
May 13-14, 2021.
David Dodd, GeoVax’s Chairman and CEO, will
deliver his corporate presentation at 9:50am ET on May 13. Mr.
Dodd will also participate in a panel discussion titled “Investing
Post COVID – Back to the Fundamentals” at 11:50am ET on May
13. The panel will discuss healthcare investing in the post
COVID world.
Investors can also request a one-on-one meeting
with Mr. Dodd to be arranged following the conclusion of the
conference. Investors can register for the conference
here: https://www.benzinga.com/events/small-cap/global/
About GeoVax
GeoVax Labs, Inc. is a clinical-stage
biotechnology company developing human vaccines against infectious
diseases and cancer using a novel patented Modified Vaccinia
Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On
this platform, MVA, a large virus capable of carrying several
vaccine antigens, expresses proteins that assemble into VLP
immunogens in the person receiving the vaccine. The production of
VLPs in the person being vaccinated can mimic virus production in a
natural infection, stimulating both the humoral and cellular arms
of the immune system to recognize, prevent, and control the target
infection. The MVA-VLP derived vaccines can elicit durable immune
responses in the host similar to a live-attenuated virus, while
providing the safety characteristics of a replication-defective
vector.
GeoVax’s current development programs are focused
on preventive vaccines against COVID-19, HIV, Zika Virus,
hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and
malaria, as well as therapeutic vaccines against multiple cancers.
The Company has designed a preventive HIV vaccine candidate to
fight against the subtype of HIV prevalent in the commercial
markets of the Americas, Western Europe, Japan, and Australia;
human clinical trials for this program are managed by the HIV
Vaccine Trials Network (HVTN) with the support of the National
Institutes of Health (NIH). GeoVax’s HIV vaccine is also part of
two separate collaborative efforts to apply its innovative gene
therapy approach toward a functional cure for HIV.
Contact:
GeoVax Labs, Inc.
investor@geovax.com
678-384-7220
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From Aug 2024 to Sep 2024
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From Sep 2023 to Sep 2024